Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
The HER2 protooncogene encodes a 185-kDa transmembrane protein (p185HER2) with extensive homology to the epidermal growth factor (EGF) receptor. Clinical and experimental evidence supports a role for overexpression of the HER2 protooncogene in the progression of human breast, ovarian, and non-small cell lung carcinoma. These data also support the hypothesis that p185HER2 present on the surface of overexpressing tumor cells may be a good target for receptor-targeted therapeutics. The anti-p185HER2 murine monoclonal antibody (muMAb) 4D5 is one of over 100 monoclonals that was derived following immunization of mice with cells overexpressing p185HER2. The monoclonal antibody is directed at the extracellular (ligand binding) domain of this receptor tyrosine kinase and presumably has its effect as a result of modulating receptor function. In vitro assays have shown that muMAb 4D5 can specifically inhibit the growth of tumor cells only when they overexpress the HER2 protooncogene. MuMAb 4D5 has also been shown to enhance the TNF-alpha sensitivity of breast tumor cells that overexpress this protooncogene. Relevant to its clinical application, muMAb 4D5 may enhance the sensitivity of p185HER2-overexpressing tumor cells to cisplatin, a chemotherapeutic drug often used in the treatment of ovarian cancer. In vivo assays with a nude mouse model have shown that the monoclonal antibody can localize at the tumor site and can inhibit the growth of human tumor xenografts which overexpress p185HER2. Modulation of p185HER2 activity by muMAb 4D5 can therefore reverse many of the properties associated with tumor progression mediated by this putative growth factor receptor. Together with the demonstrated activity of muMAb 4D5 in nude mouse models, these results support the clinical application of muMAb 4D5 for therapy of human cancers characterized by the overexpression of p185HER2.
Department of Developmental Biology, Genentech, Inc., South San Francisco, California 94080.
H M
HM
Shepard
G D
GD
Lewis
J C
JC
Sarup
B M
BM
Fendly
D
D
Maneval
J
J
Mordenti
I
I
Figari
C E
CE
Kotts
M A
MA
Palladino
A
A
Ullrich
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015870:Gene Expression; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000235:genetics / Q000628:therapy; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000276:immunology; D011519:Proto-Oncogenes; D018719:Erb-b2 Receptor Tyrosine Kinases; D014407:Tumor Cells, Cultured / Q000276:immunology
D000911:Antibodies, Monoclonal; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases